A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Have a BMI of

• ≥30 kilograms per square meter (kg/m2) or

• ≥27 kg/m2 and <30 kg/m2, with at least one of the following weight-related comorbidities:

  • Hypertension
  • Dyslipidemia
  • Cardiovascular disease
  • Obstructive sleep apnea

Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Have a prior or planned surgical treatment for obesity

Have at least one laboratory value suggestive of diabetes during screening

Use of metformin, or any other glucose-lowering medications

Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma

Have poorly controlled hypertension

Have any of the following cardiovascular conditions within 3 months prior to screening:

• acute myocardial infarction
• cerebrovascular accident (stroke)
• unstable angina, or
• hospitalization due to congestive heart failure

Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes

Have ongoing or a history of bradyarrhythmias other than sinus bradycardia

Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure

Have a history of symptomatic gallbladder disease within the past 2 years

Have signs and symptoms of any liver disease

Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality

Have a history of acute or chronic pancreatitis

Have renal impairment, measured as estimated glomerular filtration rate <30 mL/minute/1.73 m2

Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening